InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,071.63
(
0.02%
)
US TECH 100
16,868.40
(
-0.79%
)
Dow Jones
38,460.92
(
-0.11%
)
Brent Oil
87.11
(
-0.13%
)
Bitcoin
64,469.83
(
0.28%
)
Post# of 1721
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

236T568

Send PM Follow Ignore
Followers 122
Posts 43782
Boards Moderated 1
Alias Born 09/06/2012

236T568

Member Level

Re: None

Monday, 04/17/2017 10:59:05 AM

Monday, April 17, 2017 10:59:05 AM

Post# of 1721
On April 11, 2017, Insys Therapeutics, Inc. (the “Company”) accepted the resignation of Dr. Santosh Vetticaden, the interim Chief Executive Officer and Chief Medical Officer of Insys Therapeutics, Inc., whose employment will be terminated on April 28, 2017. Pursuant to the Current Report on Form 8-K previously filed with the Securities and Exchange Commission on March 27, 2017, the Company previously announced that, effective April 17, 2017, Saeed Motahari is the Company’s President and Chief Executive Officer and appointed as a member of the Company’s Board of Directors.


http://ih.advfn.com/p.php?pid=nmona&article=74348776
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up